

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Serial No.: 10/804,763  
Filing Date: March 19, 2004

### REMARKS

Entry of this amendment is respectfully requested. The amendments are made in adherence with 37 C.F.R. § 1.821-1.825. This amendment is accompanied by a floppy disc containing the above named sequences, SEQUENCE ID NUMBERS 1-51, in computer readable form, and a paper copy of the sequence information. The information contained in the computer readable disc is identical to that of the paper copy in adherence with 37 C.F.R. § 1.821(f). This amendment contains no new matter. Applicant submits that this amendment, the accompanying computer readable sequence listing, and the paper copy thereof serve to place this application in a condition of adherence to the rules 37 C.F.R. §§ 1.821-1.825.

In addition, the present amendment corrects obvious typographical errors, including erasures, alterations, overwritings, interlineations, and copy marks in Figures 3, 5, 6, 7, 8, 10A-D, 13, and 14A-B, as filed. In addition, excessive text not in accordance with 37 C.F.R. § 1.84(o) have been removed from Figures, 3, 4, 6, 11, 13, 14A-B. Replacement Sheets 20/39 to 26/39 incorporate these corrections, and Annotated Sheet Showing Changes marked in red ink are attached for the Examiner's convenience. Finally, the specification delineating these corrections has been appropriately amended by the present amendment.


No fee is believed due with this reply. However, the Commissioner is authorized to charge any required fees or credit any overpayment to Dorsey & Whitney LLP Deposit Account No. 50-2319 (Docket No. A-72186-1/TAL/DCF (471702-00008)).

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY, LLP



By:

  
David C. Foster, Reg. No. 44,685 for  
Todd A. Lorenz, Reg. No. 39,754

Dated:


July 20, 2004  
Customer No.: 32940

Dorsey & Whitney LLP  
Four Embarcadero Center, Suite 3400  
San Francisco, CA 94111-4187  
Telephone: (415) 781-1989  
Fax No. (415) 398-3249




4. Balb/c spleen cells were stimulated with CS7BL/6 spleen cells. Cultures were supplemented with normal fibroblasts (blue), medium (red) or fibroblasts with CD8 (green) of mouse (A) or human (B) origin. Cultures were harvested and tested for their lytic ability towards CS7BL/6-derived target cells.

Figure 3



Balb/c (H-2d) mice were injected with control fibroblasts (red and green) or mCD8-transfected CS7BL/6- (H-2b) derived (black and blue) fibroblasts. After two weeks animals were sacrificed, spleen cells were harvested, stimulated with CS7BL/6 (H-2b) (red and black) or CBA/J (H-2k) (blue and green) spleen cells and tested for their lytic ability on EL4 (H-2b) (red and black) or 3.AKR (H-2k) (blue and green) target cells.

Figure 4



Target cells (green) or CD8-expressing targets (red) were tested for their susceptibility to lysis by alloreactive T cells (A) or by antigen-specific CTLs (B).

Figure 5

ANNOTATED SHEET  
SHOWING CHANGES




Figure 6




FIGURE 7





FIGURE 8



~~3x10<sup>6</sup> C7BL/6 spleen cells were  
incubated with 1x10<sup>6</sup> (or no) stimulator cells,  
transduced as indicated. After 4 days the cultures  
were analyzed for presence CD4<sup>+</sup> T lymphoblasts  
by immunofluorescence.~~

**Figure 9**



FIGURE 10A

~~Infected Cells: MC57T Fibroblasts~~  
~~Panel 1: Mock-Infection; Panel 2: Infection with hAdCD8~~








FIGURE 10B

~~Infected Cells: MC57T Fibroblasts~~  
~~Panel 1: Mock-Infection; Panel 2: Infection with mAdCD8~~




**FIGURE 10C**


~~Infected Cells: Balb/c unselected bone marrow cells;~~  
~~Panel 1: Infection with lacZ Adenoviral Vector (AdLacZ);~~  
~~Panel 2: Infection with mAdCD8~~



**FIGURE 10D**

~~Infected Cells: MC57T Fibroblasts~~  
~~Panel 1: Mock-Infection;~~  
~~Panel 2: Infection with pAAV-mCD8;~~  
~~Panel 3: Infection with pAAV-hCD8~~





Fibroblasts were transduced with mAAVCD8 (B) or hAAVCD8 (D) or mock-infected (A and C). Surface expression of CD8 was detected by surface immunofluorescence (A through D). MLCs (Balb/c anti-C57BL/6) were set up in the presence of these fibroblasts that had been cultured for 0 or 5 hours after transduction before they were added to the MLCs. At end of cultures, the number of lymphoblasts was determined on a fluorescence activated cell analyzer.

Figure 11

Specific  
Release  
(%)






FIGURE 12



*+ triangle* Balb/c mice were immunized with AdLacZ (green) or mAdCD8 (red). Their spleen cells were cultured in the presence of AdLacZ and tested for specific lytic activity against AdLacZ-infected syngeneic B15 target cells.

Figure 13



*+ triangle* (A) C57BL/6 animals were immunized with AdLacZ (red) or mAdCD8 (green). Their lytic activity of their spleen cells towards syngeneic AdLacZ B14 target cells was tested. (B) Such animals were re-immunized with AdLacZ prior to testing their lytic activity against AdLacZ-infected B14 targets.

Figure 14A-B